SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
___________________________
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report March 4, 1997
CHEUNG LABORATORIES, INC.
MARYLAND
2-93826-W 52-1256615
(Commission File Numbe (IRS Employer Identification Number)
10220 Old Columbia Road Suite I Columbia, MD 21046 Phone: (410) 290-5390
March 4, 1997
Securities & Exchange Commission
Corporate Finance Division
Chief Counsel's Office
450 Fifth Street, N.W.
Washington, DC 20549-1007
RE: Cheung Laboratories, Inc.
SEC File No. 2-93826-W
Please find the attached report on Form 8-K for Cheung Laboratories, Inc.
Should you have any questions, please give us a call.
Very truly yours,
\s\ Verle D. Blaha
Verle D. Blaha
President
ITEM 5: OTHER EVENTS 8K Filing
Cheung Laboratories, Inc. (the "Registrant') has completed its first breast
cancer treatment system as part of its exclusive license agreement with
Massachusetts Institute of Technology (MIT) for the commercialization
rights to a proprietary patented Adaptive Phased Array (APA) technology to
be used in conjunction with The Registrant's hyperthermia system (Microfocus
1000) for the treatment of cancer.
The Registrant, has shipped the completed system to Massachusetts General
Hospital (MGH)East, Center for Imaging and Pharmaceutical Research (CIPR),
in Boston on a collaborative basis to evaluate the technology in an in vivo
study using animal tumor models developed at CIPR.
This innovative proprietary technology was originally developed by MIT for
use in microwave radar systems for the Department of Defense.The Registrant
believes the use of APA technology with the Registrant's Microfocus 1000
system represents a major breakthrough in the treatment of cancer using
focused heat. With the MIT-APA technology, the Registrant will be in a
position to market a complete line of state of the art, clinically effective
and side-effect free hyperthermia cancer treatment systems for breast,
prostate, liver, lung, pancreas and other deep-seated tumors.
The Registrant's Microfocus 1000 system has been approved by the Food and
Drug Administration (FDA) for cancer treatment used in conjunction with
radiation. Adding APA to the Microfocus 1000 will require clinical studies
before marketing and sales in the U.S.A. is allowed After the studies at
MGH are completed, the Registrants plans to send the system abroad for clinical
trials.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf of the
undersigned thereunto duly authorized.
CHEUNG LABORATORIES, INC.
Date: March 4, 1997 By: \s\ Verle D. Blaha
Verle D. Blaha
President